Herz MI, Lamberti JS, Mintz J, et al. A program for relapse prevention in schizophrenia: a controlled study.Arch Gen
Psychiatry 2000 Mar;57:277-83
QUESTION: In patients with schizophrenia or schizoaffective disorder, does a
programme for relapse prevention (PRP) consisting of antipsychotic medication and
psychosocial treatment prevent relapse and readmission to hospital?
Design
Randomised (allocation concealment), blinded (out.
come assessor), controlled trial with 18 months of
follow up.
Setting
A community support programme at the University of
Rochester, Rochester, New York, USA.
Patients
82 patients who were 19.60 years of age (mean age 30,
65% men), had a diagnosis of schizophrenia or schizo.
affective disorder according to DSM.III.R criteria, and
had an increased risk of relapse (>1 hospital admission
in the previous 3 years and >2 lifetime hospital
admissions). Exclusion criteria were evidence of organic
mental disorder or mental retardation, or severe drug or
alcohol dependence that required inpatient treatment.
Follow up was 86%.
Intervention
Patients were allocated to PRP treatment (n = 41) or
usual care (n = 41). All patients except two received
standard doses of maintenance antipsychotic medi.
cation (equivalent to 300.1000 mg of chlorpromazine).
PRP treatment consisted of education for patients and
family members about relapse in schizophrenia and
how to recognise prodromal symptoms and behaviour,
active monitoring for prodromal symptoms, clinical in.
tervention within 24.48 hours when prodromal
episodes were detected, 1 hour weekly supportive group
therapy (or 30.45 minutes of individual supportive
therapy for patients who refused group treatment), and
90 minutes of multifamily psychoeducation groups
biweekly for 6 months and monthly thereafter.
Main outcome measures
Relapse (score >5 on the positive scale of the Positive
and Negative Syndrome Scale and score <30 on the
Global Assessment Scale) and hospital readmission.
Main results
Fewer patients in the PRP group than in the usual care
group relapsed (P = 0.01) or were readmitted to hospital
(P = 0.03) by 18 months (table).
Conclusion
A programme for relapse prevention that combined
antipsychotic medication with psychosocial treatment
reduced relapse and hospital readmission in patients
with schizophrenia or schizoaffective disorder.